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Abstract The maximum dosage of methotrexate (MTX)
for treatment of rheumatoid arthritis (RA) formally
approved in Japan is 8 mg/week. We intended to examine
the efﬁcacy and safety of MTX at dosages over 8 mg/week
in Japanese rheumatoid arthritis patients using the large
Institute of Rheumatology, Rheumatoid Arthritis (IORRA)
cohort database. Among 9,122 patients registered in the
IORRA database from the October 2000 survey to the
October 2007 survey, 5,201 patients who had been treated
with MTX were selected. We attempted to overcome the
drawbacks innate to nonrandomized studies by using lon-
gitudinal analyses and multifactorial logistic regression
analyses. Cross-sectional analysis of data obtained from the
October 2007 survey indicated that dosages of MTX higher
than 8 mg/week were used in 27.5% of patients treated with
MTX. Longitudinal analyses based on data from three
consecutive phases showed that ﬁnal Disease Activity
Score-28 (DAS28) values were signiﬁcantly lower
[n = 260, mean difference 0.563, 95% conﬁdence interval
(CI) 0.438–0.688, P\2.2 9 10
-22, two-sided paired t test]
than initial values when MTX was increased from 8 mg/
week or lower to over 8 mg/week. In addition, longitudinal
analyses based on data from two consecutive phases indi-
cated decreases in DAS28 values of 0.26 ± 1.04 (n = 690,
P = 6.78 9 10
-11, two-sided paired t test) when MTX
dosages were increased from 8 mg/week or lower to over
8 mg/week, compared with decreases of 0.07 ± 0.89
(n = 2,125, P = 0.000307) when the dosage was main-
tained at 8 mg/week. The decreases in DAS28 values were
signiﬁcantly larger in the former than the latter
(P = 2.27 9 10
-6, two-sided unpaired t test). Concerning
safety of MTX at dosages over 8 mg/week, we performed
logistic regression analysis in which the objective variable
was the existence or nonexistence of self-reported side-
effects and the explanatory variable was the MTX dosage in
the former phase, with adjustments made for age, sex, body
mass index (BMI), steroid administration, folic acid
administration, concomitant pulmonary diseases, and renal
dysfunction. The results indicated that MTX dosages over
8 mg/week did not have any association with either severe
or severe ? moderate side-effects. These data regarding
both efﬁcacy and safety of MTX at dosages over 8 mg/week
in Japanese RA patients would provide the basis for use of
the drug at dosages currently not formally approved by the
Japanese government.
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Introduction
Methotrexate (MTX) is known to be effective for treatment
of rheumatoid arthritis (RA). Since the data from clinical
trials have indicated that MTX suppresses pain and
inﬂammation as well as progression of joint damage [1], it
is now considered to be the standard drug for treatment of
RA [2, 3].
Though MTX has already been approved for treatment
of RA in Japan, the maximum dosage indicated by the
Ministry of Health, Welfare, and Labor is only 8 mg/week,
which is much lower than the dosage applied in recent
clinical trials, where 15 to even 25 mg/week MTX was
commenced [4–10]. Indeed, according to the Guidelines
Y. Seto (&)  E. Tanaka  E. Inoue  A. Nakajima 
A. Taniguchi  S. Momohara  H. Yamanaka
Institute of Rheumatology, Tokyo Women’s Medical University,
10-22 Kawada-cho, Shinjuku-ku, Tokyo 162-0054, Japan
e-mail: seto@ior.twmu.ac.jp
123
Mod Rheumatol (2011) 21:579–593
DOI 10.1007/s10165-011-0445-4for the management of rheumatoid arthritis by the Amer-
ican College of Rheumatology (ACR) [11], the recom-
mended dosages of MTX are 7.5–20 mg/week. To be
noted, recent reports described that mortality decreased
with long-term administration of MTX [12].
In the clinical trial performed by Kashiwazaki et al.
[13], MTX was administered in weekly doses of 2–9 mg.
Based on the results of this trial and some reports by
Japanese rheumatologists [14], the maximum dosage was
set at 8 mg/week in Japan.
It has been reported that the optimal dose of MTX
differs between different patients [15]; however, antirheu-
matic effects are known to be dose dependent, and a higher
effect can be expected at higher dose [11]. Some pieces of
evidence have been obtained also in Japan that show the
dose-dependent antirheumatic effects of MTX [16], and it
is widely recognized that many Japanese RA patients
require dosages higher than 8 mg/week.
So far, no published data have provided sufﬁcient evi-
dence for the efﬁcacy and safety of MTX used at dosages
over 8 mg/week for Japanese RA patients [13]. A standard
solution to this issue would be to perform a new clinical
trial for use of MTX at over 8 mg/week in Japanese RA
patients as a new drug development process. However, it
seems unrealistic to perform a clinical trial as a new drug
development for dosages of the drug that are widely used
by most Japanese rheumatologists.
Considering this circumstance, it is highly likely that
efﬁcacy and safety at higher dosages can be examined by
analysis of data from real practice, particularly analysis of
data from a highly valuable cohort study.
In the present study, we attempt to examine both efﬁ-
cacy and safety of use of MTX in Japanese RA patients at
dosages over 8 mg/week using the IORRA cohort data-
base. Great care was taken to avoid false conclusions by
use of various statistical methods.
Patients and methods
Study cohort
The Institute of Rheumatology, Rheumatoid Arthritis
(IORRA) cohort is formed of RA patients at the Institute of
Rheumatology, Tokyo Women’s Medical University. It has
been underway since October 2000, and patients who
satisﬁed the revised classiﬁcation criteria of the American
Rheumatology Association [17] have been registered. Data
collection is conducted twice a year from each patient after
registration, and data have been obtained from 4,000–5,000
RA patients during each survey period. More speciﬁcally,
data collection is conducted twice a year, i.e., in the period
from April to May for one phase and from October to
November for the other phase; however, for simplicity in
this paper, we call these two annual phases as April and
October, respectively. The phases of different years are
numbered serially such that phase 1 denotes the time of the
survey in October 2000.
About 99% of all RA outpatients who newly visited our
institute were registered, and over 98% of them responded
to a questionnaire (often by mail) in each phase since the
establishment of the cohort. Thus, the cohort is nearly free
from bias produced by selecting only speciﬁc parts of the
patients from the outpatients; however, the problem that
the participants are from a single facility in the Tokyo area
of Japan still remains.
The data obtained from the IORRA cohort consist of the
following three elements. The ﬁrst element is formed of
objectives evaluated by the physicians, including tender
and swollen joint counts and global assessment measured
by visual analog scale (VAS). The second component is the
patient-reported information including VAS for pain, VAS
for global assessment, physical function reported by the
validated Japanese version of health assessment question-
naire (JHAQ) [18], height, weight, complications or
comorbidity during the latest 6 months, and information
about drugs from the patients during the period. To collect
the information for the second element, each patient was
given a questionnaire by the attending doctor, ﬁlled it at
home, and then mailed it to our ofﬁce within 2 weeks using
a prestamped envelope. The third element consists of the
laboratory data, which include C-reactive protein (CRP),
erythrocyte sedimentation rate (ESR), blood cell counts,
blood chemistry, and other data obtained from blood and
urine samples. Regarding safety data, information about
side-effects is obtained by patient self-report. In the IOR-
RA questionnaire, the term ‘‘side effects’’ but not ‘‘adverse
events’’ is used. The data about side-effects derive from
answers to questions about side-effects that occurred
between the last survey and the current survey, but the
exact time when the side-effect occurred cannot be deter-
mined. All data collected during each period are integrated
into a single database for analysis.
Various articles have already been published using this
database [16, 19–35]. In each phase, some patients dropped
out and other new patients were registered. However,
substantial proportions of the patients have been observed
continuously for long periods. Written informed consent
for the study was obtained from patients whenever data
were collected.
Distribution of MTX dosage by cross-sectional analysis
The distribution of the weekly dosage of MTX was
determined using data obtained in the October 2007 phase.
During this phase, data were obtained from 5,257 patients.
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and patient background for longitudinal studies
of efﬁcacy and safety of MTX at dosages higher
than 8 mg/week
This analysis may be biased if the absence of dosage data is
not independent of other events, because such associations
may inﬂuence the results of analyses of associations
between efﬁcacy (safety) and MTX dosage. To analyze
possible associations between the absence of dosage data
and other events, we compared patient background
between those with and without MTX dosage data. The
Mann–Whitney test (for continuous variables) or Fisher’s
exact test (for categorical variables) was conducted for
each background factor.
Analysis of efﬁcacy of increasing the MTX dosage
from 8 mg/week or less to over 8 mg/week using data
from three consecutive phases (‘‘phase trios’’)
For all longitudinal analyses in this study, data from
patients who had fulﬁlled the following conditions were
extracted from the IORRA database: (1) Patients registered
in the database from October 2000 (the ﬁrst survey) to
October 2007 (the 15th survey). (2) Patients over 18 years
of age at time of registration in IORRA. (3) Patients with
records of being treated with MTX. (4) Data were excluded
for periods when leﬂunomide, cyclosporine, tacrolimus or
biologics was commenced. Among the total 9,122 patients,
5,201 fulﬁlled the conditions described above, and data
were analyzed for those for whom MTX dosage data were
not missing. Patient background characteristics were
described at the phase when MTX was administered for the
ﬁrst time in patients who had been naı ¨ve to MTX, while the
data of the initial visit to our institution were regarded as
the baseline for analysis for patients who had been treated
with MTX previously.
For the analysis of the efﬁcacy of increasing the dosage
of MTX from 8 mg/week or less to over 8 mg/week, we
analyzed data from three consecutive phases, which we call
‘‘a phase trio,’’ and that of two consecutive phases (‘‘a
phase pair’’), as it is difﬁcult to identify the exact time
when the dosage was changed during the 6 months of each
phase and to conﬁrm the efﬁcacy of increasing the dosage.
Of the 5,201 patients who met the criteria, we ﬁrst selected
the cases for each of the four groups in Table 1A when the
MTX dosages in the phase trio satisﬁed the following
conditions: 8 mg/week or less at the phase before A, and
over 8 mg/week at phase A and the phase after A
(group T1); 8 mg/week or less at the phase before A, over
8 mg/week at phase A, and 8 mg/week or less at the phase
after A (group T2); 8 mg/week or less at the phase before
A, over 8 mg/week at phase A, and over 8 mg/week but
staying at the same dosage as at phase A at the phase after
A (group T3, which is also a part of group T1); 8 mg/week
through the three consecutive phases (group T4). However,
if treatments with steroid and folic acid were changed
during the period, they were excluded from each of the
groups. It is possible that multiple cases could be selected
from a patient. If this occurred, the different cases from a
patient reﬂect data for different time periods.
The primary and secondary endpoints were set as fol-
lows before performing the analyses:
Primary endpoint For phase trios that belong to
group T1, we test whether the value of DAS28 recorded
one phase after A (abbreviated as das2) is smaller than
Table 1 Deﬁnitions of the groups in the efﬁcacy analysis
Phase before A MTX dosage at
phase A (per week)
Phase after A Number of trios
(A) Phase trio
Group T1 8 mg or less Over 8 mg Over 8 mg 262
Group T2 8 mg or less Over 8 mg 8 mg or less 70
Group T3 8 mg or less Over 8 mg Over 8 mg (same value as phase A) 123
Group T4 8 mg 8 mg 8 mg 55
Phase before A MTX dosage at
phase A (per week)
Number of pairs
(B) Phase pair
Group P1 8 mg or less Over 8 mg 690
Group P2 8 mg 8 mg 2,125
Group P3 Over 8 mg Over 8 mg 2,545
There are 6-month intervals between consecutive phases
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(abbreviated as das0). The paired t test (two-sided) is
used.
Secondary endpoint 1 We test whether das2 is smaller
than das0 in the union of group T1 and T2 (all phase
trios in which the dosage of MTX had ever been
increased over 8 mg/week). The paired t test (two-sided)
is used.
Secondary endpoint 2 We test whether the value of
subtracting das2 from das0 is larger in group T3 (a
subset of phase trios in which MTX had been increased
from 8 mg/week or less to over 8 mg/week and main-
tained until one phase after A) than in group T4. The
unpaired t test (two-sided) is used.
Exploratory research For patients who belong to
group T4, we test whether das2 is smaller than das0.
The paired t test (two-sided) is used.
For each of the primary and secondary endpoints, the
hypothesis that disease activity is decreased by increasing
the MTX dosage from 8 mg/week or less to over 8 mg/
week is supported when the result of the test is signiﬁcant.
Analysis of efﬁcacy of increasing the MTX dosage
from 8 mg/week or less to over 8 mg/week using data
from two consecutive phases (‘‘phase pairs’’)
We then analyze the efﬁcacy of increasing the MTX dos-
age to over 8 mg/week using data from the following phase
pairs (Table 1B): group P1 as the phase pairs in which the
dosage of MTX was increased from 8 mg/week or less to
over 8 mg/week, group P2 as the pairs in which the dosage
was kept at 8 mg/week, and group P3 as the pairs in which
the dosage was kept over 8 mg/week. We analyzed whe-
ther the values of DAS28 in phase A were lower than those
in one phase before A for groups P1, P2, and P3 using the
paired t test, and then tested whether the difference in
DAS28 between phase A and one phase before phase A
(das0–das1) was larger for group P1 than for group P2
using an unpaired t test.
Analysis of safety of MTX administered at dosages
over 8 mg/week using data from two consecutive
phases (‘‘phase pairs’’)
In this analysis, we assumed that a self-reported event in a
phase reﬂects the dosage of MTX in the previous phase.
Therefore, for a phase pair, we analyzed the relation
between the dosage of MTX in the former phase and the
self-reported side-effects in the latter phase. The phase pairs
were stratiﬁed by MTX dosage in the former phase, and
subdivided depending on whether the dosage was the same,
increased, unknown or MTX was discontinued in the latter
phase (Table 2). Examination of only phase pairs in which
dosages of MTX were maintained would quite likely cause
bias, because either discontinuation or dosage reduction of
MTX may occur when side-effects are observed. Therefore,
we used all phase pairs in Table 2 to analyze the relation
between side-effects and the dosage of MTX.
We set the endpoints as below before the analysis. In
this analysis, we addressed the question of whether side-
effects occurred more frequently when the dosage of MTX
exceeded 8 mg/week in comparison with cases where the
dosage was 8 mg/week or less. Therefore, we performed
logistic regression analysis in which the dependent variable
was the existence or nonexistence of severe side-effects in
the latter phase, the explanatory variable was the dosage of
MTX in the former phase, and adjustments were made for
age, sex, BMI, steroid administration, folic acid adminis-
tration, pulmonary diseases, and renal dysfunction.
Primary endpoint We perform logistic regression anal-
ysis in which the dependent variable is the presence or
absence of severe to moderate side-effects by MTX
based on patient self-report, and the explanatory variable
is whether dosage of MTX is over 8 mg/week or not.
Table 2 Overview of data for safety analysis using phase pairs
In the
latter phase
MTX dosage
(mg/week) in
the former phase
2–4 Over 4–6 Over 6–8 8 or lower Over 8
Subtotal number
of phase pairs
Number of
phase pairs
% Number of
phase pairs
% Number of
phase pairs
% Number of
phase pairs
% Number of
phase pairs
%
Dosage the same
as the former
17,495 5,249 56.0 5,052 55.3 4,273 57.3 14,574 56.1 2,921 54.2
Dosage different
from the former
9,623 2,567 27.4 2,881 31.6 2,327 31.2 7,775 29.9 1,848 34.3
Discontinuation 1,417 655 7.0 345 3.8 228 3.1 1,228 4.7 189 3.5
Data not available 2,820 909 9.7 852 9.3 628 8.4 2,389 9.2 431 8.0
Total 31,355 9,380 100.0 9,130 100.0 7,456 100.0 25,966 100.0 5,389 100.0
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analysis in which the dependent variable is the presence
or absence of severe side-effects by MTX, that by any
drugs, and the presence or absence of severe to moderate
side-effects by any drug based on patient self-report,
respectively, and the explanatory variable is whether
dosage of MTX is over 8 mg/week or not.
Analyses of efﬁcacy of MTX at dosages
over 8–16 mg/week by longitudinal study
We extracted phase pairs where the MTX dosages in two
consecutive phases satisﬁed the following conditions:
group E1 for phase pairs in which the dosage of MTX was
increased from less than 16 mg/week to 16 mg or more per
week, group E2 for 14 mg/week, group E3 for 12 mg/
week, group E4 for 10 mg/week, and group E5 for pairs in
which MTX was stable at dosage of 8 mg/week, respec-
tively. We allowed the extraction of more than one phase
pair from each patient. The endpoints were as follows:
Primary endpoint For group E1, the paired t test is used
to examine whether the value of DAS28 in phase A is
lower than the value in one phase before A.
Secondary endpoints 1–3 For each of group E2, E3, and
E4, the paired t test is used to examine whether the value
of DAS28 in phase A is lower than the value in one
phase before A.
Secondary endpoints 4–7 The difference between the
value of DAS28 in one phase before A and in phase A is
denoted as das0–das1. The unpaired t test is used to
examine whether the mean of das0–das1 for each of
groups E1–E4 is larger than the mean of group E5.
Exploratory research For group E5, the paired t test is
used to examine whether the value of DAS28 in phase A
is lower than the value in one phase before A.
Analyses of safety of MTX at dosages
over 8–16 mg/week by longitudinal study
In the analyses for dosages over 8–16 mg/week, we made
the same assumption as in the previous analysis of the
safety of MTX administered at dosages over 8 mg/week.
We selected phase pairs divided into the following groups:
group S1 for phase pairs in which the dosage of MTX was
16 mg/week or higher in the phase before A (phase A
represents the phase in which an adverse event is reported),
group S2 for those in which the dosage of MTX was from
14 to lower than 16 mg/week, group S3 for those in which
it was from 12 to lower than 14 mg/week, group S4 for
those in which it was from 10 to lower than 12 mg/week,
and group S5 for those in which the dosage of MTX was
8 mg/week (Table 3). We performed logistic regression
analysis in which the dependent variable was the existence
or nonexistence of severe or moderate to severe side-
effects in the latter phase, the explanatory variable was the
dosage of MTX in the former phase, and adjustments were
made for age, sex, BMI, steroid administration, folic acid
administration, pulmonary diseases, renal dysfunction, and
DAS28 at phase A.
Results
Distribution of MTX dosage by cross-sectional analysis
Among 5,257 patients whose data were in the database
obtained during the October 2007 phase, the number of
patients treated with MTX was 3,252 (61.9%). Figure 1
shows the distribution of the dosage of MTX in the 3,252
MTX-treated patients, in which dosages of MTX per
patient were 7.54 ± 3.05 mg/week (mean ± standard
deviation). Among them, 27.5% of patients were treated
with MTX dosage higher than 8 mg/week, 11.5% higher
than 12 mg/week, and 0.83% higher than 16 mg/week
(Fig. 1).
Examination of associations between missing data
and patient background for longitudinal studies
of efﬁcacy and safety of MTX at dosages higher
than 8 mg/week
Table 4 presents the background of the 5,201 patients who
matched conditions 1–4 in the ‘‘Patients and methods’’
Table 3 Grouping for studies of associations between adverse events and dosages of MTX
MTX dosage (per week) Number of
phase pairs
Fraction (%) of
patients with severe
adverse events
Fraction (%) of patients
with severe or moderate
adverse events Phase before A Phase A
Group S1 16 mg or higher Any 192 3.28 13.06
Group S2 From 14 to lower than 16 mg Any 655 3.13 14.06
Group S3 From 12 to lower than 14 mg Any 1,488 4.43 14.81
Group S4 From 10 to lower than 12 mg Any 3,199 3.09 13.91
Group S5 8 mg Any 5,574 3.34 14.47
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between patients with and without dosage data after
Bonferroni correction for multiple comparisons (P\
0.05/29 = 0.00172) included age at onset (P =
0.00000027), age (P = 0.000000000013), and folic acid
dose (P = 0.00036) (Table 5). In addition, steroid
(P = 0.0030) and bucillamine (P = 0.0036) showed rela-
tively low P values after analysis of the association with
missing dosage data, although the associations were not
signiﬁcant after correction for multiple comparisons.
By performing logistic regression analysis with missing
and nonmissing event as the dependent variable and the
explanatory variables mentioned above, we found that only
age was signiﬁcantly associated (P = 0.018) with missing
dosage data whereas the associations with the other factors
were not signiﬁcant (detailed data not shown).
In any case, patients with missing dosage data consti-
tuted only about 3% of the patients in the dataset, and the
absence of dosage data seems to have a small effect.
However, results should be interpreted with care if a var-
iable is strongly associated with age in the following
consecutive analyses.
Analysis of efﬁcacy of increasing the dosage of MTX
from 8 mg/week or less to over 8 mg/week using data
from three consecutive phases (‘‘phase trios’’)
Table 6 shows the background of the patients in each group
ofTable 1.ItisclearthatdiseaseactivityonephasebeforeA
in group T4 is lower than in group T1 or T3 at baseline; the
mean value of DAS28 one phase before A in group T1 was
4.30 ± 1.21 (n = 260, mean ± SD), while it was 3.66 ±
1.23(n = 55)forgroup T4(P\0.001,unpairedttest;two-
sided) (Table 6). In addition, the meanCRP value one phase
before A in group T1 was 2.00 ± 2.19 mg/dl (n = 256),
while it was 1.00 ± 1.71 mg/dl (n = 52) for group T4
(P\0.0005) (Table 6). Namely, the disease activity before
increasing the dosage of MTX from 8 mg/week or less to
over 8 mg/week was signiﬁcantly higher than the disease
activity for phase trios without such an increase. A similar
difference was observed for the data in phase A. The mean
DAS28 value in phase A was 4.00 ± 1.18 (n = 251) in
group T1, while it was 3.49 ± 1.16 (n = 52) for group T4
(P\0.005) (Table 6). As previously stated, age was sig-
niﬁcantly associated with missing MTX dosage data. We
therefore compared age between groups T1 and T4. The
mean age in group T1 was 53.33 ± 12.54 years (n = 262),
while it was 53.85 ± 12.91 years (n = 55) in group T4
(Table 6), not signiﬁcantly different (P = 0.785).
The results of the analyses using data for phase trios are
summarized in Fig. 2. In each of the analyses with primary
endpoint and secondary endpoint 1, we obtained a positive
estimated value for das0–das2, and the test was signiﬁcant.
In contrast, for the phase trios in which dosages of MTX
were maintained at 8 mg/week (group T4), there were no
signiﬁcant differences between the DAS28 values between
one phase before A and one phase after A (P = 0.060,
Fig. 2).
For differences between the DAS28 value for one phase
before A and one phase after A (das0–das2), we tested
whether the mean value for group T3 was different from
the mean value for group T4 (secondary endpoint 2). The
mean value of das0–das2 for group T3 tended to be larger
than for group T4, but the difference was not signiﬁcant
(P = 0.096) (Fig. 2).
The above-mentioned results indicate that RA activity is
decreased by increasing the dosage of MTX from 8 mg/
week or less to over 8 mg/week. In contrast, RA activity
did not signiﬁcantly decrease when the dosage of 8 mg/
week was maintained.
Analysis of efﬁcacy of increasing the dosage of MTX
from 8 mg/week or less to over 8 mg/week using data
from two consecutive phases (‘‘phase pairs’’)
The DAS28 values in phase A were lower than those one
phase before A for any of groups P1, P2, and P3 (Fig. 3,
see Table 1B for group deﬁnition). Thus, for group P1
(n = 690), the DAS values (das0) one phase before A were
4.21 ± 1.17 and those (das1) in phase A were 3.95 ± 1.20
(P = 6.78 9 10
-11), 3.62 ± 1.17 and 3.55 ± 1.18 (P =
0.000307) for group P2 (n = 2125), and 3.65 ± 1.14
and 3.54 ± 1.16 (P = 2.19 9 10
-10) for group P3 (n =
2545), respectively.
The decrease in DAS28 for group P1 from one phase
before A to phase A was more remarkable than in
group P2. Thus, the values of das0–das1 for group P1
and group P2 were 0.26 ± 1.04 and 0.07 ± 0.89,
Fig. 1 Histogram of MTX dosage in 3,252 patients (IORRA October
2007 survey)
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(P = 2.27 9 10
-6).
The above results indicate that increase in the dosage of
MTX from 8 mg/week or less to over 8 mg/week sup-
presses RA activity more effectively than keeping the
dosage at 8 mg/week or lower.
Analysis of safety of MTX administered at dosages
over 8 mg/week using data from two consecutive
phases (‘‘phase pairs’’)
Of the extracted pairs, in 54–58% the MTX dosage in the
latter was equal to the dosage in the former (Table 2); in
Table 4 Background of 5,201 patients in whom MTX was administered for the ﬁrst time
Variable Number of
missing data
Mean value
(fraction)
Standard
deviation
Median 25
percentile
75
percentile
Minimum
value
Maximum
value
Sex Male 0 and female 1 0 0.84
Age at onset (years) 70 46.34 13.54 47 37 56 1 87
Age (years) 0 55.46 12.78 57 48 65 18 89
Duration of RA (years) 70 9.12 8.48 7 3 13 0 66
Height cm 65 157.15 7.34 157 152 162 126 187
Weight kg 91 52.92 9.14 52 47 58 25 97
BMI kg/m
2 101 21.38 3.01 21.09 19.23 23.18 12.23 39.72
DAS28–ESR
a 432 4.16 1.21 4.11 3.321 4.94 0.5015 8.644
JHAQ
b 12 0.88 0.74 0.75 0.25 1.375 0 3
Number of tender joints (45 joints) 241 4.16 5.51 2 1 5 0 43
Number of swollen joints (45 joints) 241 3.74 4.36 2 1 5 0 41
Pain–VAS
c 100 mm 43 37.80 26.19 33 15 59 0 100
GH
d 100 mm 38 38.71 24.83 38 17 56 0 100
Doctor–VAS
e 100 mm 71 25.23 19.19 21 10 35 0 100
CRP mg/dl 190 1.68 2.14 0.9 0.3 2.2 0 27.5
ESR mm/h 219 40.80 25.13 36.7 21 56.58 1.4 115.9
RF U/ml 220 145.87 246.98 64 23 144 1 2940
GPT IU/l 215 21.60 21.28 16 12 24 3 446
GOT IU/l 218 21.52 13.09 18 15 24 5 253
WBC 1/mm
3 282 7,645.72 2,295.12 7,300 6,000 9,000 2,400 20,300
RF (±) U/ml 0 0.82
NSAID Fraction 0 0.81
Steroid Fraction 0 0.59
MTX Fraction 0 1.00
BUC Fraction 0 0.19
SSZ Fraction 0 0.23
DPC Fraction 0 0.05
GST Fraction 0 0.06
MTX dosage mg/week 132 5.25 2.26 4.4 4 6 2 18
PSL dosage
f mg/day 120 5.04 4.74 5 3 6 0.03 200
Folic acid Fraction 0 0.12
RF rheumatoid factor, GPT glutamic pyruvic transaminase, GOT glutamic oxaloacetic transaminase, WBC white blood cell, NSAID nonsteroidal
anti-inﬂammatory drug, BUC bucillamine, SSZ salazosulfapyridine, DPC D-penicillamine, GST gold sodium thiomalate
a DAS28-ESR DAS28 calculated using the value of erythrocyte sedimentation rate (ESR) (a score indicating RA activity proposed by the
European League against Rheumatism; data of 28 joints are used to calculate the score)
b JHAQ answer to Japanese version of health assessment questionnaire (JHAQ, [18])
c Patient’s assessment of pain measured by visual analogue scale (VAS) represented by length (maximum 100 mm)
d Patient’s global assessment measured by VAS represented by length (maximum 100 mm)
e Physician’s global assessment of disease activity measured by VAS represented by length (maximum 100 mm)
f Dosage of steroid (in terms of prednisolone)
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123the other pairs, the dosage was changed, administration
was stopped or data were missing in the latter phase. The
fraction of the phase pairs without dosage data in the latter
phase was less than 10% (Table 2). Among the phase pairs
whose dosages of MTX in the former phase were over
8 mg/week, the fractions of discontinuation and missing
data in the latter phase were 3.5% and 8.0%, respectively
(Table 2). These fractions were not larger than those in the
other phase pairs with lower dosages of MTX. Thus,
among the phase pairs with other dosages of MTX, the
fractions of discontinuation and missing data in the latter
phase were 3.1–7.0% and 8.4–9.7%, respectively
(Table 2).
Results of the analyses for the primary endpoint and the
secondary endpoints 1–3 indicated that no statistical sig-
niﬁcant associations were present between the dosage of
MTX (over 8 mg/week or not) and the presence or the
absence of self-reported side-effects (Table 7).
Analysis of efﬁcacy of MTX at dosages
over 8–16 mg/week by longitudinal study
For groups E1, E2, E3, E4, and E5, the numbers of phase
pairs extracted were 62, 140, 267, 499, and 2,125,
respectively (Fig. 4). Concerning the primary endpoint,
das0 values were 4.26 ± 1.17 while das1 values were
Table 5 Comparison of patients with and without MTX dosage data
Variable Patients with missing MTX
dosage data (132)
Patients with MTX dosage
data (5,069)
Difference
of means
P value
Number of
missing data
Mean value
(fraction)
Standard
deviation
Number of
missing data
Mean value
(fraction)
Standard
deviation
Sex Male 0 and
female 1
0 0.82 0 0.84 -0.02 0.55
Age at onset (years) 3 52.44 13.30 67 46.18 13.51 6.26 0.00000027
Age (years) 0 62.46 11.79 0 55.28 12.76 7.18 0.000000000013
Duration of RA (years) 3 9.88 8.51 67 9.10 8.48 0.78 0.19
Height cm 4 155.54 7.12 61 157.20 7.35 -1.66 0.018
Weight kg 4 52.62 8.49 87 52.92 9.15 -0.31 0.76
BMI kg/m
2 4 21.70 2.83 97 21.37 3.02 0.33 0.053
DAS28–ESR 17 4.35 1.22 415 4.15 1.21 0.20 0.10
JHAQ 2 0.99 0.79 10 0.88 0.74 0.12 0.10
Number of tender
joints
(45 joints) 10 4.81 6.30 231 4.15 5.49 0.66 0.25
Number of swollen
joints
(45 joints) 10 4.19 5.40 231 3.73 4.33 0.46 0.58
Pain–VAS 100 mm 4 39.45 27.38 39 37.76 26.16 1.69 0.52
GH 100 mm 5 39.54 25.52 33 38.69 24.81 0.85 0.78
Doctor–VAS 100 mm 4 23.65 17.08 67 25.27 19.24 -1.62 0.57
CRP mg/dl 3 2.08 2.42 187 1.67 2.13 0.41 0.037
ESR mm/h 4 46.41 27.92 215 40.66 25.04 5.76 0.029
RF U/ml 3 142.82 228.65 217 145.95 247.47 -3.13 0.65
GPT IU/l 5 20.97 17.98 210 21.62 21.36 -0.65 0.28
GOT IU/l 5 22.65 12.30 213 21.49 13.11 1.15 0.19
WBC 1/mm
3 8 7731.45 2,220.06 274 7,643.50 2,297.21 87.95 0.56
RF (±) U/ml 0 0.81 0 0.82 -0.01 0.73
NSAID Fraction 0 0.73 0 0.81 -0.08 0.033
Steroid Fraction 0 0.46 0 0.59 -0.13 0.0030
BUC Fraction 0 0.10 0 0.20 -0.10 0.0036
SSZ Fraction 0 0.18 0 0.23 -0.05 0.18
DPC Fraction 0 0.08 0 0.05 0.02 0.23
GST Fraction 0 0.07 0 0.06 0.01 0.56
PSL dosage mg/day 8 5.48 2.23 112 5.03 4.77 0.45 0.0353
Folic acid Fraction 0 0.03 0 0.12 -0.09 0.00036
Abbreviations are explained in Table 4
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1233.86 ± 1.20 for group E1. The mean value of das1 was
signiﬁcantly lower than that of das0 (difference between
means of 0.399, P = 0.00063) (Fig. 4). Moreover, con-
cerning the secondary endpoints 1–3, the average value of
DAS28 in phase A was lower than that one phase before A
in each of group E2, E3, and E4 (differences of
0.268–0.449, P = 2.08 9 10
-8, P = 3.27 9 10
-12,
P = 1.41 9 10
-9, respectively, Fig. 4).
In addition, concerning the exploratory research, the
average value of DAS28 in phase A was also signiﬁcantly
lower (difference of 0.07) than one phase before A even in
group E5. Though the difference of the average DAS28
was the least in group E5 among all the groups, the result
of the test was signiﬁcant, probably because of the large
sample size (P = 0.00031, Fig. 4). Next, concerning the
secondary endpoints 4–7, we performed unpaired t tests to
examine whether the mean of das0–das1 for group E5 was
different from each of the means for the other groups.
We found that the mean decrease (das0–das1) in DAS28
for each of group E1, E2, E3, and E4 was signiﬁcantly
larger than that for group E5 (Fig. 4). For instance, in the
comparison between group E1 and group E5, the differ-
ence of the mean value of das0–das1 was 0.329
[P = 0.0041, unpaired t test (two-sided)].
These data indicate that increases in the dosage of MTX
from 10 mg/week or less to over 10 mg/week, from 12 mg/
week or less to over 12 mg/week, from 14 mg/week or less
to over 14 mg/week, and from 16 mg/week or less to over
16 mg/week led to signiﬁcant reductions in DAS28. In
addition, the size of the average decrease in DAS28 for
each of those groups was signiﬁcantly larger than that in
the group in which the dosage of MTX was maintained at
8 mg/week.
Analysis of safety of MTX at dosages
over 8–16 mg/week by longitudinal study
The fractions of patients with severe side-effects based on
self-report were 3.09–4.43%, and the fractions of patients
with severe or moderate side-effects based on self-reports
were 13.06–14.81% (Table 3). Unexpectedly, the fraction
of patients with side-effects was lower among patients who
received MTX at 16 mg/week or higher than in those
whose dosage of MTX was kept at 8 mg/week. These
results probably reﬂect the tendency for physicians to
administer lower dosages of MTX to higher-risk patients,
while they administer higher dosages to lower-risk patients.
Moreover, it is easily imaginable that physicians tend to
maintain MTX dosages in higher-risk patients and tend to
increase the dosages of MTX in lower-risk patients.
Based on the above notion, we performed logistic
regression analysis in which adjustment was made for age,
BMI, steroid administration, folic acid administration,
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123history of pulmonary diseases, history of renal dysfunction,
and DAS28 value one phase before A, which may be
recognized as risks by physicians. In the logistic regression,
the dependent variable was the presence or absence of
severe side-effects or severe to moderate side-effects, and
explanatory variables were group S1 versus group S5,
group S2 versus group S5, group S3 versus group S5, and
group S4 versus group S5 (as levels 0 and 1), in addition to
the above-mentioned eight variables.
Table 8 presents the results of the logistic regression
analysis. In the case where the dependent variable of the
model was presence or absence of severe side-effects, three
variables, i.e. steroid administration (P = 0.000041),
history of pulmonary diseases (P = 2.16 9 10
-7), and
DAS28 in phase A (P = 0.000024), were signiﬁcantly
associated. In the case where the dependent variable was
severe to moderate side-effects, BMI (P = 0.002) and folic
acid administration (P = 2.42 9 10
-9) were positively
associated with the presence of side-effects, in addition to
steroid administration (P = 3.39 9 10
-15), history of
pulmonary diseases (P = 9.55 9 10
-6), and DAS28 in
phase A (P = 2.92 9 10
-9). Though it is reasonable from
the medical point of view that steroid administration,
leanness, history of pulmonary diseases, and higher disease
activity were positively associated with side-effects, it is
hard to understand why folic acid administration tends to
cause side-effects. The positive association between folic
acid administration and side-effects probably reﬂects the
tendency for this drug to be administered when side-effects
take place.
Importantly, however, there was no association between
the presence of severe side-effects or the presence of severe
to moderate side-effects and the difference between
group S5 and any of groups S1–S4. To summarize, we
found no evidence that the safety of MTX administered at
dosages of 10, 12, 14 or 16 mg/week or more was lower
than the safety of MTX administered at the dosage of
8 mg/week.
Discussion
In the present study, we examined whether dosages of
MTX over 8 mg/week are beneﬁcial from the viewpoints
of both efﬁcacy and safety using cohort data from the
IORRA database.
There are beneﬁts and drawbacks in examining efﬁcacy
and safety by analysis of such cohort data rather than
clinical trial data. The drawbacks include the following
problems: (a) both physicians and patients were aware of
the contents of the treatments, (b) this is not a controlled
trial in which placebo was used, and (c) no randomization
was done. On the other hand, it has beneﬁts that a ran-
domized controlled trial does not possess. Firstly, it can
provide data from a larger number of patients for longer
time periods. In cohort-based studies, data such as rare
side-effects or long-term effects may be obtained. For
example, rare side-effects from MTX include pneumonitis
and myelosuppression, both of which are hard to analyze in
Fig. 2 Results of longitudinal analyses for efﬁcacy of MTX at
dosages higher than 8 mg/week using data from three consecutive
phases; changes in DAS28 values were examined in the 4 different
groups in Table 1A. Asterisk Primary endpoint: Number of phase
trios is 260. The difference of means is 0.563 [95% conﬁdence
interval (0.438, 0.688), t test statistic 8.88, P value \2.2 9 10
-22].
Dagger Secondary endpoint 1: Number of phase trios is 330. The
difference of means is 0.519 [95% conﬁdence interval (0.408, 0.629),
t test statistic 9.20, P value\2.2 9 10
-22]. Double dagger Secondary
endpoint 2: Number of phase trios is 121 versus 55. The difference of
means is 0.287 [95% conﬁdence interval (-0.05, 0.38), t test statistic
1.67, P value 0.096]. Section symbol Exploratory research: Number of
phase trios is 55. The difference of means is 0.238 [95% conﬁdence
interval (-0.010, 0.487), t test statistic 1.92, P value 0.06]
Fig. 3 Results of longitudinal analysis for efﬁcacy of MTX at
dosages higher than 8 mg/week using data from two consecutive
phases; changes in DAS28 values were examined in the three
different groups in Table 1B. Test of the difference between DAS28
decrease in group P1 and that in group P2: P = 2.27 9 10
-6
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for a short period of time. In the present study in which the
sample size is larger and the observation periods are
longer, rare but severe side-effects including such events
may be analyzed. Secondly, data from a cohort study
reﬂect routine medical practice rather than an artiﬁcial
situation. In a randomized controlled trial, the sample often
reﬂects only a small proportion of the entire patients
because of strict enrolment criteria applied to make the
targets as uniform as possible and the results of the test as
clear as possible. Such drawbacks of randomized
controlled trials may be weaker in cohort studies. Thirdly,
the ethical problem is smaller in cohort studies than in
randomized controlled trials. In the latter case, use of
placebo and randomization may force patients to undergo
inappropriate treatments.
When simple associations were tested between dosages
of MTX and disease activity, higher dosages were associ-
ated with higher disease activity. This is as expected but
would be a strong confounder in the present study. Simi-
larly, higher dosage was associated with lower frequency
of side-effects. This is also as expected but would also be a
strong confounder. Those associations, of course, reﬂect
the attitudes of physicians to adjust dosages of MTX
according to disease activity, concomitant medical condi-
tions, and side-effects. We attempted to overcome such
drawbacks of nonrandomized studies by using longitudinal
analyses and multifactorial logistic regression analyses.
Our longitudinal analyses based on phase trios and
phase pairs indicated that increase in the dosage of MTX
from 8 mg/week or lower to over 8 mg/week decreased RA
activity compared with cases where MTX dosages were
Table 7 Results of longitudinal
safety analysis using phase pairs
a See text for the deﬁnitions of
the endpoints
b Maximum-likelihood estimate
of the slope in the logistic
regression analysis
c P value of the test for the null
hypothesis that the slope is zero
Fraction (%) of patients
who reported adverse events
in the group with dosage
of 8 mg/week or lower
Fraction (%) of patients
who reported adverse events
in the group with dosage
over 8 mg/week
Regression
coefﬁcient
b
P value
c
Primary
endpoint
a
4.88 5.16 -0.0351 0.63
Secondary
endpoint 1
0.92 1.10 0.119 0.45
Secondary
endpoint 2
3.66 4.02 -0.0096 0.91
Secondary
endpoint 3
14.60 16.90 0.0384 0.38
Fig. 4 Results of longitudinal analysis of efﬁcacy of increasing MTX
dosage from lower than 10–16 to 10–16 mg/week or higher; changes
in DAS28 values were examined in 5 different groups. Asterisk
difference of means is 0.399 [95% conﬁdence interval (0.178, 0.621),
P value \0.00063]. Difference from group E5 is 0.329 (P value
0.0041). Dagger difference of means is 0.430 [95% conﬁdence
interval (0.287, 0.572), P value \2.08 9 10
-8]. Difference from
group E5 is 0.360 (P value 0.0000036). Double dagger difference of
means is 0.449 [95% conﬁdence interval (0.328, 0.569), P value
\3.27 9 10
-12]. Difference from group E5 is 0.379 (P value
1.37 9 10
-10). Section symbol difference of means is 0.268 [95%
conﬁdence interval (0.183, 0.353), P value \1.41 9 10
-9]. Differ-
ence from group E5 is 0.198 (P value 0.000012). Double asterisk
difference of means is 0.070 [95% conﬁdence interval (0.032, 0.108),
P value\0.00031]
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123maintained. Concerning safety, we found no signiﬁcant
increases in the frequencies of severe or severe ? moder-
ate side-effects by the increase in the dosage of MTX from
8 mg/week or lower to over 8 mg/week.
The results of the present study indicate that 27.5% of
patients treated with MTX were administered dosages over
8 mg/week in the Institute of Rheumatology, Tokyo
Women’s Medical University. Although many Japanese
rheumatologists are using MTX at dosages over 8 mg/
week, this is not ofﬁcially approved. Therefore, in clinical
trials whose data are to be included in documents for new
drug approval by the Japanese government, the 8 mg/week
restriction is applied. Thus, even in recent clinical studies
in which the effects of biological agents were tested with or
without MTX, dosages of MTX not more than 8 mg/week
were used [36, 37].
Hashiramoto et al. [38] recently reported the results
from a prospective study in which 8 mg/week MTX was
used. They concluded that such a low dosage of MTX
appeared to be favorable; however, it is clearly insufﬁcient
and cannot halt progression of rheumatic joint destruction.
MTX has been approved for use in patients with juvenile
idiopathic arthritis (JIA) by the Japanese government. This
approval was granted without data from clinical trials
sponsored by the pharmaceutical company; rather, it was
achieved by collecting necessary information through
ongoing efforts (including collection and analysis of
information about approval status in other countries, ade-
quate evidence from the literature, implementation of a
clinical use survey in Japan, etc.) [16, 19–35]. Curiously,
the maximum dosage (10 mg/m
2/week) was set on the basis
of pharmacokinetic data from children, rather than relying
on the dosing method and dose for adults. Since the average
body surface area of the Japanese men is around 1.68 m
2,
some children with JIA can take much higher doses of MTX
than formally approved for adult RA patients.
Since insufﬁcient evidence has been provided for the
efﬁcacy and safety of MTX dosages over 8 mg/week in
Table 8 Logistic regression analysis for study of association between adverse events and dosage of MTX over 8 mg/week
Variable Estimated value
of slope
Odds
ratio
Lower bound
(95% CI)
Upper bound
(95% CI)
Signiﬁcance
(P value)
(A) Severe side-effect
Cutoff -4.2640 0.014 0.005 0.040 9.02E-16
Group S1 versus group S5 -0.0122 0.988 0.428 2.280 0.977
Group S2 versus group S5 0.2976 1.347 0.882 2.057 0.169
Group S3 versus group S5 -0.0421 0.959 0.679 1.355 0.811
Group S4 versus group S5 -0.0179 0.982 0.761 1.268 0.891
Sex -0.1624 0.850 0.631 1.146 0.287
Age -0.0031 0.997 0.988 1.006 0.499
BMI 0.0029 1.003 0.967 1.040 0.874
Steroid 0.5566 1.745 1.337 2.277 0.0000412
Folic acid 0.1394 1.150 0.921 1.435 0.218
Pulmonary diseases 1.1545 3.172 2.051 4.908 2.16E-07
Renal dysfunction -0.5538 0.575 0.078 4.253 0.588
DAS28 at phase A 0.1901 1.209 1.107 1.321 0.000024
(B) Severe ? moderate side-effect
Cutoff -2.0443 0.129 0.074 0.226 5.51E-13
Group S1 versus group S5 0.0279 1.028 0.662 1.597 0.901
Group S2 versus group S5 0.1100 1.116 0.875 1.424 0.376
Group S3 versus group S5 0.0685 1.071 0.897 1.278 0.448
Group S4 versus group S5 0.0733 1.076 0.942 1.230 0.282
Sex 0.0312 1.032 0.872 1.220 0.716
Age -0.0035 0.996 0.992 1.001 0.152
BMI -0.0311 0.969 0.950 0.989 0.002
Steroid 0.5381 1.713 1.498 1.958 3.39E-15
Folic acid 0.3595 1.433 1.273 1.612 2.42E-09
Pulmonary diseases 0.6902 1.994 1.469 2.707 9.55E-06
Renal dysfunction 0.3250 1.384 0.625 3.066 0.423
DAS28 at phase A 0.1438 1.155 1.101 1.211 2.92E-09
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123Japanese RA patients, the results of the present study will
serve as the basis for Japanese rheumatologists to use MTX
at dosages over 8 mg/week.
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